"Doesn’t this mean that the medical establishment wants to blame Cadegiani both for giving drugs that don’t work, and for not giving them to enough people?"
The main points were that he had ethics approval for a small study, on mild/moderate patients, in a single hospital in the Brazilian capital, and somehow the study ended up being conducted in several hospitals, in critical patients, in the Brazilian Amazon. Also, the consent forms handled to patients were not the same as the ones initially approved, and didn't contain many passages about patients rights.
This study had a 50% mortality rate in the control group, with a significant amount of hepatic and renal failure. The author says they were in the placebo group, but that wouldn't have been known as the deaths were happening, as it was a blind study and there was no effort on the part of the author to request unblinding to check if maybe the renal and hepatic toxicity was because of the maybe renal and hepatotoxic drugs. When requested, the author did not provide any data to provide the traceability of the medication, so it can't be ruled out that the placebo group was actually receiving medication. The "Independent data monitoring comitee" in the study was under the supervision of someone on the payroll of the pharmaceutical company making proxalutamide
So, either the study was properly blinded and he decided to not report excess Kinsley and failure deaths which could presumably be linked to the new, barely-tested drug, which would be a crime, or he knew that the placebo group had an overwhelming amount of excess deaths and didn't try to prematurely end the study, causing willful harm to the patients, which also would be a crime
I haven't been able to find any news on the subject since the police raid on the author's house last August, but this is unsurprising given the slow pace of the Brazilian justice system
"Doesn’t this mean that the medical establishment wants to blame Cadegiani both for giving drugs that don’t work, and for not giving them to enough people?"
There are several pieces of context missing in this interpretation; here is a public note by the Brazilian Research Ethics Comitee https://conselho.saude.gov.br/ultimas-noticias-cns/2095-nota-publica-cns-elucida-a-sociedade-brasileira-fatos-sobre-estudo-irregular-com-proxalutamida (in Portuguese, but Google translate works well)
The main points were that he had ethics approval for a small study, on mild/moderate patients, in a single hospital in the Brazilian capital, and somehow the study ended up being conducted in several hospitals, in critical patients, in the Brazilian Amazon. Also, the consent forms handled to patients were not the same as the ones initially approved, and didn't contain many passages about patients rights.
This study had a 50% mortality rate in the control group, with a significant amount of hepatic and renal failure. The author says they were in the placebo group, but that wouldn't have been known as the deaths were happening, as it was a blind study and there was no effort on the part of the author to request unblinding to check if maybe the renal and hepatic toxicity was because of the maybe renal and hepatotoxic drugs. When requested, the author did not provide any data to provide the traceability of the medication, so it can't be ruled out that the placebo group was actually receiving medication. The "Independent data monitoring comitee" in the study was under the supervision of someone on the payroll of the pharmaceutical company making proxalutamide
So, either the study was properly blinded and he decided to not report excess Kinsley and failure deaths which could presumably be linked to the new, barely-tested drug, which would be a crime, or he knew that the placebo group had an overwhelming amount of excess deaths and didn't try to prematurely end the study, causing willful harm to the patients, which also would be a crime
I haven't been able to find any news on the subject since the police raid on the author's house last August, but this is unsurprising given the slow pace of the Brazilian justice system